Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.

导出 LinkOut

翻译打印收藏纠错

作者： Richard,LeBlanc ^[1] ; Imran,Ahmad ^[2] ; Rafik,Terra ^[3] ; Jean-Samuel,Boudreault ^[4] ; David,Ogez ^[5] ; Kristopher,Lamore ^[6] ; Jean-Sébastien,Delisle ^[2] ; Nadia,Bambace ^[2] ; Léa,Bernard ^[2] ; Sandra,Cohen ^[2] ; Thomas,Kiss ^[2] ; Silvy,Lachance ^[2] ; Séverine,Landais ^[3] ; Émilie,Lemieux-Blanchard ^[7] ; Guy,Sauvageau ^[2] ; Michael,Sebag ^[8] ; Denis Claude,Roy ^[2] ; Jean,Roy ^[2]

作者单位： Division of Hematology, Oncology and Transplantation, Hôpital Maisonneuve-Rosemont, Department of Medicine/Université de Montréal, Montreal, QC, Canada. richard.leblanc.1@umontreal.ca. ^[1] Division of Hematology, Oncology and Transplantation, Hôpital Maisonneuve-Rosemont, Department of Medicine/Université de Montréal, Montreal, QC, Canada. ^[2] Division of Hematology, Oncology and Transplantation, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada. ^[3] Division of Hematology and Oncology, Hôpital du Sacré-Coeur, Department of Medicine/Université de Montréal, Montreal, QC, Canada. ^[4] Chronic Pain Clinic, Hôpital Maisonneuve-Rosemont, Department of Anesthesiology and Pain Medicine/Université de Montréal, Montreal, QC, Canada. ^[5] Laboratoire de psychopathologie et processus de santé, Université de Paris, Paris, Boulogne-Billancourt, France. ^[6] Division of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal, Department of Medicine/Université de Montréal, Montreal, QC, Canada. ^[7] Division of Hematology, McGill University Health Center, Department of Medicine/McGill University, Montreal, QC, Canada. ^[8]